NEW YORK – Agilent Technologies said on Wednesday that it has signed an agreement with San Francisco-based startup InterVenn to investigate glycoproteomic biomarkers for diseases common in Southeast Asia, such as cancer.
The team plans to begin development work at InterVenn Malaysia's laboratory at Technology Park Malaysia in Kuala Lumpur.
Launched in 2018 by researchers at the University of California, Davis and Stanford University, InterVenn is commercializing glycoproteomic analysis methods for a variety of cancers, including ovarian and colorectal cancer. The firm's glycoprotein analysis enables mass spec-based analysis of glycopeptides in a patient's serum.
"This partnership goes a long way toward realizing InterVenn's long-held vision to establish a Center of Excellence of Glycoproteomics for Southeast Asia," Aldo Carrascoso, CEO of InterVenn, said in a statement. "This new laboratory will be the first of its kind, offering diagnostic tools based on the science of glycoproteomics for the healthcare needs of the more than 650 million citizens of the region."
Financial details of the agreement were not disclosed.
"Agilent is very excited to become a strategic partner with InterVenn in the establishment of a Center of Excellence of Glycoproteomics," Robin Philp, academia and collaborations manager at Agilent, said in a statement. "The opportunity to engage in the area of clinical measurement and especially for diseases such as cancer is of great importance and of societal benefit."